Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's disease.

MLA

Macaluso, Fabio Salvatore, et al. “Vedolizumab May Be an Effective Option for the Treatment of Postoperative Recurrence of Crohn’s Disease.” Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, vol. 54, no. 5, May 2022, pp. 629–34. EBSCOhost, https://doi.org/10.1016/j.dld.2021.11.021.

APA

Macaluso, F. S., Cappello, M., Crispino, F., Grova, M., Privitera, A. C., Piccillo, G., Magnano, A., Ferracane, C., Belluardo, N., Giangreco, E., Fries, W., Viola, A., Di Mitri, R., Mocciaro, F., Camilleri, S., Garufi, S., Renna, S., Casà, A., Maida, M., & Orlando, A. (2022). Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn’s disease. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 54(5), 629–634. https://doi.org/10.1016/j.dld.2021.11.021

Chicago

Macaluso, Fabio Salvatore, Maria Cappello, Federica Crispino, Mauro Grova, Antonino Carlo Privitera, Giovita Piccillo, Antonio Magnano, et al. 2022. “Vedolizumab May Be an Effective Option for the Treatment of Postoperative Recurrence of Crohn’s Disease.” Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 54 (5): 629–34. doi:10.1016/j.dld.2021.11.021.